SEC Form 4
Rocket Pharmaceuticals, Inc. (RCKT) insider trading
In the 12 months to Nov 15, 2026, 6 RCKT insiders reported open-market sales of $1.0M across 27 filings; one director bought $34.4K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $1.0M
- 27 filings · 6 insiders
- Open-market purchases
- $34.4K
- 1 filing · Elisabeth Bjork, Director
Who traded RCKT, and when
- Purchase
- Sale
RCKT daily close from Nov 17, 2025 to Nov 13, 2026, between $2.18 and $5.30, last $2.30. 27 sale and 1 purchase filings by 7 insiders, marked at their filing dates. Martin Wilson, General Counsel: sold $462.4K across 9 filings, first filed Nov 20, 2025, last Nov 9, 2026. Gaurav Shah, CEO: sold $285.7K across 8 filings, first filed Nov 20, 2025, last Aug 20, 2026. Christopher James Stevens, Chief Operating Officer: sold $128.3K across 1 filing, first filed Aug 13, 2026, last Aug 13, 2026. Sarbani Chaudhuri, Officer (see filing): sold $95.5K across 3 filings, first filed May 11, 2026, last Nov 12, 2026. Elisabeth Bjork, Director: bought $34.4K across 1 filing, first filed Jan 6, 2026, last Jan 6, 2026. John Militello, Officer (see filing): sold $23.7K across 5 filings, first filed Nov 20, 2025, last May 21, 2026. Jonathan David Schwartz, Officer (see filing): sold $7.6K across 1 filing, first filed Nov 20, 2025, last Nov 20, 2025.
Largest mark · tap a row for others
Martin Wilson · General Counsel
Sale $256,464
75,364 shares at $3.40 avg
Filed Sep 15, 2026 · traded Sep 11
Close on filing date $3.41
Martin Wilson · General Counsel
General Counsel
$462.4K soldGaurav Shah · CEO
CEO
$285.7K soldChristopher James Stevens · Chief Operating Officer
Chief Operating Officer
$128.3K soldSarbani Chaudhuri · Officer (see filing)
Officer (see filing)
$95.5K soldElisabeth Bjork · Director
Director
$34.4K boughtJohn Militello · Officer (see filing)
Officer (see filing)
$23.7K soldJonathan David Schwartz · Officer (see filing)
Officer (see filing)
$7.6K soldOpen-market trades
28 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Martin Wilson | General Counsel | $462.4K | — | 9 | — | |
| Gaurav Shah | CEO | $285.7K | — | 8 | — | |
| Christopher James Stevens | Chief Operating Officer | $128.3K | — | 1 | — | |
| Sarbani Chaudhuri | Officer (see filing) | $95.5K | — | 3 | — | |
| Elisabeth Bjork | Director | — | $34.4K | 1 | — | |
| John Militello | Officer (see filing) | $23.7K | — | 5 | — | |
| Jonathan David Schwartz | Officer (see filing) | $7.6K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Sarbani Chaudhuri Officer (see filing) | Sale | 4,872 | $2.33 | $11.3K | 257,937 | |
traded | Martin Wilson General Counsel | Sale | 53,389 | $2.39 | $127.8K | 545,100 | |
traded | Martin Wilson General Counsel | Sale | 75,364 | $3.40 | $256.5K | 598,489 | |
traded | Gaurav Shah CEO | Sale | 2,293 | $3.38 | $7.8K | 1,056,594 | |
traded | Martin Wilson General Counsel | Sale | 631 | $3.38 | $2.1K | 673,853 | |
traded | Martin Wilson General Counsel | Sale | 3,493 | $3.38 | $11.8K | 674,484 | |
traded | Gaurav Shah CEO | Sale | 2,837 | $3.38 | $9.6K | 1,058,887 | |
traded | Sarbani Chaudhuri Officer (see filing) | Sale | 4,701 | $3.50 | $16.4K | 262,809 | |
traded | Christopher James Stevens Chief Operating Officer | Sale | 36,658 | $3.50 | $128.3K | 505,784 | |
traded | Gaurav Shah CEO | Sale | 55,684 | $3.09 | $171.8K | 1,061,724 | |
traded | John Militello Officer (see filing) | Sale | 384 | $3.01 | $1.2K | 89,780 | |
traded | Martin Wilson General Counsel | Sale | 662 | $3.01 | $2.0K | 677,977 | |
traded | Gaurav Shah CEO | Sale | 2,409 | $3.01 | $7.3K | 1,040,918 | |
traded | John Militello Officer (see filing) | Sale | 855 | $3.61 | $3.1K | 90,164 | |
traded | Gaurav Shah CEO | Sale | 2,728 | $3.61 | $9.8K | 1,043,327 | |
traded | Martin Wilson General Counsel | Sale | 3,361 | $3.61 | $12.1K | 678,639 | |
traded | Sarbani Chaudhuri Officer (see filing) | Sale | 17,650 | $3.84 | $67.7K | 267,510 | |
traded | Martin Wilson General Counsel | Sale | 1,376 | $3.34 | $4.6K | 682,000 | |
traded | Gaurav Shah CEO | Sale | 5,990 | $3.34 | $20.0K | 1,046,055 | |
traded | John Militello Officer (see filing) | Sale | 1,157 | $3.34 | $3.9K | 91,019 | |
traded | Gaurav Shah CEO | Sale | 12,279 | $3.31 | $40.7K | 1,052,045 | |
traded | John Militello Officer (see filing) | Sale | 3,726 | $3.31 | $12.3K | 92,176 | |
traded | Martin Wilson General Counsel | Sale | 12,253 | $3.31 | $40.6K | 683,376 | |
traded | Elisabeth Bjork Director | Purchase | 10,000 | $3.44 | $34.4K | 50,000 | |
traded | Martin Wilson General Counsel | Sale | 1,646 | $2.98 | $4.9K | 383,816 | |
traded | Gaurav Shah CEO | Sale | 6,276 | $2.98 | $18.7K | 778,296 | |
traded | Jonathan David Schwartz Officer (see filing) | Sale | 2,545 | $2.98 | $7.6K | 299,064 | |
traded | John Militello Officer (see filing) | Sale | 1,086 | $2.98 | $3.2K | 65,920 |
GET /stocks/filings/vX/form-4?tickers=RCKT&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RCKT"
],
"issuer_cik": "0001281895",
"owner_cik": "0002064940",
"accession_number": "0001140361-26-043480",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-09",
"issuer_name": "ROCKET PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "RCKT",
"owner_name": "Chaudhuri Sarbani",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "See Remarks",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-09",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4872,
"transaction_price_per_share": 2.327,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 257937,
"transaction_value": 11337.144,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Holdings include Restricted Stock Units (\"RSUs\") that convert to common stock on a one-for-one basis."
},
{
"id": "F2",
"description": "The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs."
}
],
"remarks": "Chief Commercial & Medical Affairs Officer"
},
{
"tickers": [
"RCKT"
],
"issuer_cik": "0001281895",
"owner_cik": "0001704342",
"accession_number": "0001140361-26-042784",
"form_type": "4",
"filing_date": "2026-11-09",
"period_of_report": "2026-11-05",
"issuer_name": "ROCKET PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "RCKT",
"owner_name": "Wilson Martin",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "General Counsel",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 53389,
"transaction_price_per_share": 2.394,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 545100,
"transaction_value": 127813.266,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Holdings include Restricted Stock Units (\"RSUs\") that convert to common stock on a one-for-one basis."
},
{
"id": "F2",
"description": "The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 15 records
- Option exercises1 record
- Grants and awards13 records
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Rocket Pharmaceuticals, Inc.'s CEO sold stock?
Yes. Gaurav Shah (CEO) sold 90,496 shares ($285.7K) between Nov 2025 and Aug 2026.
How current is RCKT’s insider data?
These are RCKT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RCKT insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RCKT every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.